Rituximab, lenalidomide
Phase 2Recruiting 0 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Primary CNS Lymphoma
Conditions
Primary CNS Lymphoma
Trial Timeline
Nov 2, 2020 → Nov 2, 2026
NCT ID
NCT04627753About Rituximab, lenalidomide
Rituximab, lenalidomide is a phase 2 stage product being developed by Celltrion for Primary CNS Lymphoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04627753. Target conditions include Primary CNS Lymphoma.
What happened to similar drugs?
20 of 20 similar drugs in Primary CNS Lymphoma were approved
Approved (20) Terminated (6) Active (0)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04627753 | Phase 2 | Recruiting |
Competing Products
20 competing products in Primary CNS Lymphoma